Silk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 95, Issue , 2015, Pages 271-278

  Lovett, Michael L ^a,b   Wang, Xiaoqin ^a   Yucel, Tuna ^a,b   York, Lyndsey ^a   Keirstead, Marc ^a   Haggerty, Linda ^a   Kaplan, David L ^a  

^a Tufts University   (United States)

^b Ekteino Laboratories   (United States)

Author keywords

Bevacizumab; Biodegradation; Controlled release; Hydrogel; Silk fibroin; Sustained drug delivery

Indexed keywords

BEVACIZUMAB; SILK FIBROIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; DELAYED RELEASE FORMULATION; FIBROIN; HYDROGEL; SILK; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; BIODEGRADATION; BIOLOGICAL ACTIVITY; BLOOD ANALYSIS; BODY WEIGHT; CHEMOSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEGRADATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG STABILITY; DUTCH BELTED (RABBIT); EXPERIMENTAL RABBIT; EYE INJURY; EYE IRRITATION; EYE REDNESS; GELATION; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; LIMIT OF QUANTITATION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OCULAR IRRITATION; PLASMA; SUSTAINED DRUG RELEASE; VITREOUS BODY; WEIGHT GAIN; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG RELEASE; INTRAOCULAR DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; RABBIT; TIME FACTOR;

ADMINISTRATION, OPHTHALMIC; ANGIOGENESIS INHIBITORS; ANIMALS; BEVACIZUMAB; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; FIBROINS; HYDROGELS; INTRAVITREAL INJECTIONS; RABBITS; SILK; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84943819063     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.12.029     Document Type: Article

References (45)

1. W.L. Wong, X. Su, X. Li, C.M.G. Cheung, R. Klein, C.Y. Cheng, and T.Y. Wong Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis Lancet Glob. Health 2 2014 e106 e116
2. L.S. Lim, P. Mitchell, J.M. Seddon, F.G. Holz, and T.Y. Wong Age-related macular degeneration Lancet 379 2012 1728 1738
3. K.M. Gehrs, D.H. Anderson, L.V. Johnson, and G.S. Hageman Age-related macular degeneration - emerging pathogenetic and therapeutic concepts Ann. Med. 38 2006 450 471
4. M. Van Lookeren Campagne, J. Lecouter, B.L. Yaspan, and W. Ye Mechanisms of age-related macular degeneration and therapeutic opportunities J. Pathol. 232 2014 151 164
5. N.M. Bressler Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update Retina 25 2005 119 134
6. S.G. Schwartz, I.U. Scott, H.W. Flynn Jr, and M.W. Stewart Drug delivery techniques for treating age-related macular degeneration Expert Opin. Drug Deliv. 11 2014 61 68
7. N. Papadopoulos, J. Martin, Q. Ruan, A. Rafique, M.P. Rosconi, E. Shi, E.A. Pyles, G.D. Yancopoulos, N. Stahl, and S.J. Wiegand Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Angiogenesis 15 2012 171 185
8. D.F. Martin, M.G. Maguire, S.L. Fine, G.S. Ying, G.J. Jaffe, J.E. Grunwald, C. Toth, M. Redford, and F.L. Ferris Iii Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
9. M.W. Stewart Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF Expert Rev. Clin. Pharmacol. 7 2014 167 180
10. J.S. Heier, D.M. Brown, V. Chong, J.F. Korobelnik, P.K. Kaiser, Q.D. Nguyen, B. Kirchhof, A. Ho, Y. Ogura, G.D. Yancopoulos, N. Stahl, R. Vitti, A.J. Berliner, Y. Soo, M. Anderesi, G. Groetzbach, B. Sommerauer, R. Sandbrink, C. Simader, and U. Schmidt-Erfurth Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
11. B. Bakall, J.C. Folk, H.C. Boldt, E.H. Sohn, E.M. Stone, S.R. Russell, and V.B. Mahajan Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab Am. J. Ophthalmol. 156 2013 15 22 e11
12. K. Numata, P. Cebe, and D.L. Kaplan Mechanism of enzymatic degradation of beta-sheet crystals Biomaterials 31 2010 2926 2933
13. R. Rajkhowa, X. Hu, T. Tsuzuki, D.L. Kaplan, and X. Wang Structure and biodegradation mechanism of milled Bombyx mori silk particles Biomacromolecules 13 2012 2503 2512
14. Y. Wang, D.D. Rudym, A. Walsh, L. Abrahamsen, H.J. Kim, H.S. Kim, C. Kirker-Head, and D.L. Kaplan In vivo degradation of three-dimensional silk fibroin scaffolds Biomaterials 29 2008 3415 3428
15. L. Meinel, S. Hofmann, V. Karageorgiou, C. Kirker-Head, J. McCool, G. Gronowicz, L. Zichner, R. Langer, G. Vunjak-Novakovic, and D.L. Kaplan The inflammatory responses to silk films in vitro and in vivo Biomaterials 26 2005 147 155
16. B. Panilaitis, G.H. Altman, J. Chen, H.J. Jin, V. Karageorgiou, and D.L. Kaplan Macrophage responses to silk Biomaterials 24 2003 3079 3085
17. F.P. Seib, M.F. Maitz, X. Hu, C. Werner, and D.L. Kaplan Impact of processing parameters on the haemocompatibility of Bombyx mori silk films Biomaterials 33 2012 1017 1023
18. D.N. Rockwood, R.C. Preda, T. Yucel, X. Wang, M.L. Lovett, and D.L. Kaplan Materials fabrication from Bombyx mori silk fibroin Nat. Protoc. 6 2011 1612 1631
19. L.S. Wray, X. Hu, J. Gallego, I. Georgakoudi, F.G. Omenetto, D. Schmidt, and D.L. Kaplan Effect of processing on silk-based biomaterials: reproducibility and biocompatibility J. Biomed. Mater. Res. B Appl. Biomater. 99 2011 89 101
20. J. Zhang, E. Pritchard, X. Hu, T. Valentin, B. Panilaitis, F.G. Omenetto, and D.L. Kaplan Stabilization of vaccines and antibiotics in silk and eliminating the cold chain Proc. Natl. Acad. Sci. U.S.A. 109 2012 11981 11986
21. E.M. Pritchard, P.B. Dennis, F. Omenetto, R.R. Naik, and D.L. Kaplan Review: physical and chemical aspects of stabilization of compounds in silk Biopolymers 97 2012 479 498
22. S. Lu, X. Wang, Q. Lu, X. Hu, N. Uppal, F.G. Omenetto, and D.L. Kaplan Stabilization of enzymes in silk films Biomacromolecules 10 2009 1032 1042
23. N.A. Guziewicz, A.J. Massetti, B.J. Perez-Ramirez, and D.L. Kaplan Mechanisms of monoclonal antibody stabilization and release from silk biomaterials Biomaterials 34 2013 7766 7775
24. S. Inoue, K. Tanaka, F. Arisaka, S. Kimura, K. Ohtomo, and S. Mizuno Silk fibroin of Bombyx mori is secreted, assembling a high molecular mass elementary unit consisting of H-chain, L-chain, and P25, with a 6:6:1 molar ratio J. Biol. Chem. 275 2000 40517 40528
25. U.J. Kim, J.Y. Park, C.M. Li, H.J. Jin, R. Valluzzi, and D.L. Kaplan Structure and properties of silk hydrogels Biomacromolecules 5 2004 786 792
26. X.Q. Wang, J.A. Kluge, G.G. Leisk, and D.L. Kaplan Sonication-induced gelation of silk fibroin for cell encapsulation Biomaterials 29 2008 1054 1064
27. T. Yucel, P. Cebe, and D.L. Kaplan Vortex-induced injectable silk fibroin hydrogels Biophys. J. 97 2009 2044 2050
28. G.G. Leisk, T.J. Lo, T. Yucel, Q. Lu, and D.L. Kaplan Electrogelation for protein adhesives Adv. Mater. 22 2010 711 715
29. T. Diab, E.M. Pritchard, B.A. Uhrig, J.D. Boerckel, D.L. Kaplan, and R.E. Guldberg A silk hydrogel-based delivery system of bone morphogenetic protein for the treatment of large bone defects J. Mech. Behav. Biomed. Mater. 11 2012 123 131
30. A.M. Hopkins, L. De Laporte, F. Tortelli, E. Spedden, C. Staii, T.J. Atherton, J.A. Hubbell, and D.L. Kaplan Silk hydrogels as soft substrates for neural tissue engineering Adv. Funct. Mater. 23 2013 5140 5149
31. N. Guziewicz, A. Best, B. Perez-Ramirez, and D.L. Kaplan Lyophilized silk fibroin hydrogels for the sustained local delivery of therapeutic monoclonal antibodies Biomaterials 32 2011 2642 2650
32. United States Pharmacopeia National Formulary USP 34 NF 29 2011 United States Pharmacopeial Convention Rockville, MD
33. G. Cantone, Ninety Day Ocular Pharmacokinetic Evaluation following an Intravitreal Injection of Bevacizumab-loaded Silk Hydrogels in Dutch Belted Rabbits, Toxicon Final Non-GLP Report: 11-130-N1, Toxikon Corporation, Bedford, MA, 2011.
34. V. Hsei, G.G. DeGuzman, A. Nixon, and J. Gaudreault Complexation of VEGF with bevacizumab decreases VEGF clearance in rats Pharm. Res. 19 2002 1753 1756
35. Y. Zhang, M. Huo, J. Zhou, and S. Xie PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel Comput. Methods Programs Biomed. 99 2010 306 314
36. S.J. Bakri, M.R. Snyder, J.M. Reid, J.S. Pulido, and R.J. Singh Pharmacokinetics of intravitreal bevacizumab (Avastin) Ophthalmology 114 2007 855 859
37. R. Elia, D.R. Newhide, P.D. Pedevillano, G.R. Reiss, M.A. Firpo, E.W. Hsu, D.L. Kaplan, G.D. Prestwich, and R.A. Peattie Silk-hyaluronan-based composite hydrogels: a novel, securable vehicle for drug delivery J. Biomater. Appl. 27 2013 749 762
38. B.B. Mandal, S. Kapoor, and S.C. Kundu Silk fibroin/polyacrylamide semi-interpenetrating network hydrogels for controlled drug release Biomaterials 30 2009 2826 2836
39. T. Yucel, M.L. Lovett, and D.L. Kaplan Silk-based biomaterials for sustained drug delivery J. Control. Release 190 2014 381 397
40. T. Dyakonov, C.H. Yang, D. Bush, S. Gosangari, S. Majuru, and A. Fatmi Design and characterization of a silk-fibroin-based drug delivery platform using naproxen as a model drug J. Drug Deliv. 2012 2012 490514
41. A. Giteau, M.C. Venier-Julienne, A. Aubert-Pouessel, and J.P. Benoit How to achieve sustained and complete protein release from PLGA-based microparticles? Int. J. Pharm. 350 2008 14 26
42. T. Estey, J. Kang, S.P. Schwendeman, and J.F. Carpenter BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems J. Pharm. Sci. 95 2006 1626 1639
43. Y. Peng, M. Ang, S. Foo, W.S. Lee, Z. Ma, S.S. Venkatraman, and T.T. Wong Biocompatibility and biodegradation studies of subconjunctival implants in rabbit eyes PLoS ONE 6 2011 e22507
44. A. Motta, C. Migliaresi, F. Faccioni, P. Torricelli, M. Fini, and R. Giardino Fibroin hydrogels for biomedical applications: preparation, characterization and in vitro cell culture studies J. Biomater. Sci. Polym. Ed. 15 2004 851 864
45. M. Santin, A. Motta, G. Freddi, and M. Cannas In vitro evaluation of the inflammatory potential of the silk fibroin J. Biomed. Mater. Res. 46 1999 382 389